Tirzepatide is the first dual GLP-1/GIP receptor agonist approved for clinical use. Understanding how it works requires understanding the two incretins it activates simultaneously.
Tirzepatide is a once-weekly subcutaneous peptide injection. It works by activating two distinct incretin receptors at once — GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Activation produces appetite suppression via central nervous system signaling, delayed gastric emptying, glucose-dependent insulin secretion, glucagon suppression, and improved insulin sensitivity in adipose tissue. The combined dual activation is the mechanism behind tirzepatide producing the highest mean weight loss of any approved GLP-1 medication. Onset of effects is typically within 1-2 weeks; peak effect on weight is observed at 60-72 weeks.
NexLife is structured around clinical best practices for tirzepatide. The same flat-rate pricing applies across the entire titration schedule ($186/mo on the 12-month plan from 2.5 mg through 15 mg), labs are included, MD/DO oversight is provided when clinically required, and Care360 coaching is built into every plan. See full NexLife review.
Compounded semaglutide + tirzepatide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000